EHA congress presentation on June 13 may generate attention; watch for any partnership or licensing interest that could validate the platform and extend cash runway. No IND filed yet — clinical testing timeline remains the key catalyst to monitor.
Price Chart
Executive Summary
Evaxion announced new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, showing successful expression/secretion in human cells and specific immune responses with targeted cell-killing. Data will be presented at the EHA 2026 Congress on June 13. This is an early-stage, non-clinical milestone for a pre-revenue biotech with no financial figures or regulatory filing trigger, making it a modest positiveEntwicklung but not a material near-term catalyst.
Key Facts
- EVX-04, an off-the-shelf therapeutic vaccine for AML, achieved complete expression and secretion in human cells, enabling immune recognition and activation
- All 16 ERV antigen fragments included in EVX-04 drive specific immune responses in mice (in vivo) and human cells (in vitro) and induce targeted cell-killing
- Poster presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden on June 13, 2026
- Company states it is preparing regulatory filing for clinical testing
- AML has ~25% 3-year overall survival for elderly patients ineligible for intensive treatment, signaling high unmet need
Financial Impact
No financial figures reported; pre-revenue clinical-stage company. Potential future value depends on successful IND filing and eventual clinical data
Risk Factors
- EVX-04 is pre-clinical; no human efficacy or safety data yet and regulatory filing for clinical testing has not been submitted
- Evaxion has a history of negative stock drift post-filings (avg T+20 alpha -13.2%, 0% win rate) and is a pre-revenue biotech requiring ongoing capital — any equity offering would dilute current holders
- Preclinical results may not translate to clinical success; AML is a competitive space with existing immunotherapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004043 |
| Document: f6k_061026.htm | 0001171843-26-004043 |
| Document: 0001171843-26-004043-index-headers.html | 0001171843-26-004043 |
| Document: 0001171843-26-004043-index.html | 0001171843-26-004043 |
| Document: 0001171843-26-004043.txt | 0001171843-26-004043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access